Abstract
Depressive symptoms and abnormal glycolipid metabolisms are common in patients with Parkinson’s disease (PD), but their relationship has not been fully reported. It is not clear whether glycolipid impairments lead to poor cognitive and motor function, and aggravate depressive symptoms. Therefore, we aimed to explore the relationships between glycolipid variables, cognition, motor and depressive symptoms in PD patients cross-sectionally. Two hundred ten PD patients were recruited. Glycolipid parameters and Uric acid (UA) were measured. Depressive symptoms, cognitive function and motor symptoms were assessed using the Hamilton Depression Rating Scale-17 (HAMD-17), the Montreal Cognitive Assessment (MOCA) and the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part-III (UPDRS-III). Depressive PD patients had significantly worse motor symptoms and higher levels of fasting plasma glucose (FPG) than those in non-depressive patients (F = 24.145, P < 0.001). Further, logistic regression analysis indicated that UPDRS-III (OR = 1.039, 95% CI 1.019–1.057, P = 0.044), FPG (OR = 1.447, 95% CI 1.050–1.994, P = 0.024) were independently associated with depression. In PD patients without depression, UA (β = − 0.068, t = − 2.913, P = 0.005) and cholesterol (CHOL) (β = − 3.941, t = − 2.518, P = 0.014) were independent predictors of the UPDRS-III score; in addition, UPDRS-III score was negatively associated with MOCA score (β = − 0.092, t = − 2.791, P = 0.007). FPG levels and motor symptoms were related to depressive symptoms in PD patients. Further, in non-depressive PD patients, UA and CHOL showed putative biomarkers of motor symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding authors Jie Li and Shen Li upon reasonable request.
References
Ascherio A, Schwarzschild MA (2016) The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 15(12):1257–1272. https://doi.org/10.1016/s1474-4422(16)30230-7
Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Schwarzschild MA (2020) Associations of lower caffeine intake and plasma urate levels with idiopathic Parkinson’s disease in the Harvard biomarkers study. J Parkinsons Dis 10(2):505–510. https://doi.org/10.3233/jpd-191882
Bartoli F, Trotta G, Crocamo C, Malerba MR, Clerici M, Carra G (2018) Antioxidant uric acid in treated and untreated subjects with major depressive disorder: a meta-analysis and meta-regression. Eur Arch Psychiatry Clin Neurosci 268(2):119–127. https://doi.org/10.1007/s00406-017-0817-7
Bech P (2015) The responsiveness of the different versions of the Hamilton depression scale. World Psychiatry 14(3):309–310. https://doi.org/10.1002/wps.20248
Black CN, Bot M, Scheffer PG, Snieder H, Penninx B (2018) Uric acid in major depressive and anxiety disorders. J Affect Disord 225:684–690. https://doi.org/10.1016/j.jad.2017.09.003
Chen S, Zhang Q, Dai G, Hu J, Zhu C, Su L, Wu X (2016) Association of depression with pre-diabetes, undiagnosed diabetes, and previously diagnosed diabetes: a meta-analysis. Endocrine 53(1):35–46. https://doi.org/10.1007/s12020-016-0869-x
Chung HS, Lee JS, Kim JA, Roh E, Lee YB, Hong SH, Choi KM (2021) Fasting plasma glucose variability in midlife and risk of Parkinson’s disease: a nationwide population-based study. Diabetes Metab 47(3):101195. https://doi.org/10.1016/j.diabet.2020.08.006
Constantinescu R, Andreasson U, Holmberg B, Zetterberg H (2013) Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. Acta Neurol Scand 127(2):e8-12. https://doi.org/10.1111/ane.12012
Cooney JW, Stacy M (2016) Neuropsychiatric issues in Parkinson’s disease. Curr Neurol Neurosci Rep 16(5):49. https://doi.org/10.1007/s11910-016-0647-4
de Lau LML, Breteler MMB (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535. https://doi.org/10.1016/s1474-4422(06)70471-9
de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005) Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 58(5):797–800. https://doi.org/10.1002/ana.20663
De Virgilio A, Greco A, Fabbrini G, Inghilleri M, Rizzo MI, Gallo A, de Vincentiis M (2016) Parkinson’s disease: autoimmunity and neuroinflammation. Autoimmun Rev 15(10):1005–1011. https://doi.org/10.1016/j.autrev.2016.07.022
Dong MX, Feng X, Xu XM, Hu L, Liu Y, Jia SY, Wei YD (2018) Integrated analysis reveals altered lipid and glucose metabolism and identifies NOTCH2 as a biomarker for Parkinson’s disease related depression. Front Mol Neurosci 11:257. https://doi.org/10.3389/fnmol.2018.00257
Elbaz A, Carcaillon L, Kab S, Moisan F (2016) Epidemiology of Parkinson’s disease. Rev Neurol (paris) 172(1):14–26. https://doi.org/10.1016/j.neurol.2015.09.012
Fu X, Wang Y, He X, Li H, Liu H, Zhang X (2020) A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson’s disease. Lipids Health Dis 19(1):97. https://doi.org/10.1186/s12944-020-01284-w
Gallagher DA, Schrag A (2012) Psychosis, apathy, depression and anxiety in Parkinson’s disease. Neurobiol Dis 46(3):581–589. https://doi.org/10.1016/j.nbd.2011.12.041
Gao X, O’Reilly EJ, Schwarzschild MA, Ascherio A (2016) Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology 86(6):520–526. https://doi.org/10.1212/WNL.0000000000002351
Goldman JG, Postuma R (2014) Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol 27(4):434–441. https://doi.org/10.1097/wco.0000000000000112
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatr 23:56–62. Retrieved from https://pubmed.ncbi.nlm.nih.gov/14399272
Huang T, Rifas-Shiman SL, Ertel KA, Rich-Edwards J, Kleinman K, Gillman MW, James-Todd T (2015a) Pregnancy hyperglycaemia and risk of prenatal and postpartum depressive symptoms. Paediatr Perinat Epidemiol 29(4):281–289. https://doi.org/10.1111/ppe.12199
Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Chen H (2015b) Statins, plasma cholesterol, and risk of Parkinson’s disease: a prospective study. Mov Disord 30(4):552–559. https://doi.org/10.1002/mds.26152
Huang TT, Hao DL, Wu BN, Mao LL, Zhang J (2017) Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway. Biochem Biophys Res Commun 493(4):1443–1449. https://doi.org/10.1016/j.bbrc.2017.10.004
Huang XX, Ng SYE, Chia NSY, Acharyya S, Setiawan F, Lu ZH, Tan LCS (2018) Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson’s disease: PALS study. Parkinsonism Relat Disord 55:50–54. https://doi.org/10.1016/j.parkreldis.2018.05.010
Jagadeesan AJ, Murugesan R, Vimala Devi S, Meera M, Madhumala G, Vishwanathan Padmaja M, Pathak S (2017) Current trends in etiology, prognosis and therapeutic aspects of Parkinson’s disease: a review. Acta Biomed 88(3):249–262. https://doi.org/10.23750/abm.v88i3.6063
Jain S, Ton TG, Boudreau RM, Yang M, Thacker EL, Studenski S, Newman AB (2011) The risk of Parkinson disease associated with urate in a community-based cohort of older adults. Neuroepidemiology 36(4):223–229. https://doi.org/10.1159/000327748
Keener AM, Paul KC, Folle A, Bronstein JM, Ritz B (2018) Cognitive impairment and mortality in a population-based Parkinson’s disease cohort. J Parkinsons Dis 8(2):353–362. https://doi.org/10.3233/jpd-171257
Kessing LV, Rytgaard HC, Ekstrøm CT, Knop FK, Berk M, Gerds TA (2020) Antidiabetes agents and incident depression: a nationwide population-based study. Diabetes Care 43(12):3050–3060. https://doi.org/10.2337/dc20-1561
Kia DA, Noyce AJ, White J, Speed D, Nicolas A, Burgess S, Collaborators, I (2018) Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson’s disease. Annal Neurol 84(2):191–199. https://doi.org/10.1002/ana.25294
Kobylecki CJ, Nordestgaard BG, Afzal S (2018) Plasma urate and risk of Parkinson’s disease: A mendelian randomization study. Ann Neurol 84(2):178–190. https://doi.org/10.1002/ana.25292
Kohler O, Krogh J, Mors O, Benros ME (2016a) Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol 14(7):732–742. https://doi.org/10.2174/1570159x14666151208113700
Kohler S, Cierpinsky K, Kronenberg G, Adli M (2016b) The serotonergic system in the neurobiology of depression: relevance for novel antidepressants. J Psychopharmacol 30(1):13–22. https://doi.org/10.1177/0269881115609072
Léger J, Fjellestad-Paulsen A, Bargiacchi A, Doyen C, Ecosse E, Carel JC, Le Heuzey MF (2017) Can growth hormone treatment improve growth in children with severe growth failure due to anorexia nervosa? A preliminary pilot study. Endocr Connect 6(8):839–846. https://doi.org/10.1530/ec-17-0200
Li YR, Zhao LY, Yu DM, Ding GQ (2019) Associations between serum uric acid and depression among middle-aged and elderly participants in China. Psychol Health Med 24(10):1277–1286. https://doi.org/10.1080/13548506.2019.1622748
Lim SY, Lang AE (2010) The nonmotor symptoms of Parkinson’s disease—an overview. Mov Disord 25(Suppl 1):S123-130. https://doi.org/10.1002/mds.22786
Lintel H, Corpuz T, Paracha SUR, Grossberg GT (2021) Mood disorders and anxiety in Parkinson’s disease: current concepts. J Geriatr Psychiatry Neurol 34(4):280–288. https://doi.org/10.1177/08919887211018267
Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, Emre M (2012) Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Mov Disord 27(3):349–356. https://doi.org/10.1002/mds.24893
Lord S, Galna B, Coleman S, Burn D, Rochester L (2013) Mild depressive symptoms are associated with gait impairment in early Parkinson’s disease. Mov Disord 28(5):634–639. https://doi.org/10.1002/mds.25338
Lubomski M, Davis RL, Sue CM (2020) Depression in Parkinson’s disease: perspectives from an Australian cohort. J Affect Disord 277:1038–1044. https://doi.org/10.1016/j.jad.2020.09.032
Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ (2018) Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol 17(6):559–568. https://doi.org/10.1016/s1474-4422(18)30127-3
Marogianni C, Sokratous M, Dardiotis E, Hadjigeorgiou GM, Bogdanos D, Xiromerisiou G (2020) Neurodegeneration and inflammation—an interesting interplay in Parkinson’s disease. Int J Mol Sci. https://doi.org/10.3390/ijms21228421
Marques A, Dutheil F, Durand E, Rieu I, Mulliez A, Fantini ML, Durif F (2018) Glucose dysregulation in Parkinson’s disease: too much glucose or not enough insulin? Parkinsonism Relat Disord 55:122–127. https://doi.org/10.1016/j.parkreldis.2018.05.026
Marsh L (2013) Depression and Parkinson’s disease: current knowledge. Curr Neurol Neurosci Rep 13(12):409. https://doi.org/10.1007/s11910-013-0409-5
Mollenhauer B, Rochester L, Chen-Plotkin A, Brooks D (2014) What can biomarkers tell us about cognition in Parkinson’s disease? Mov Disord 29(5):622–633. https://doi.org/10.1002/mds.25846
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Chertkow H (2005) The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53(4):695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Ng A, Chander RJ, Tan LC, Kandiah N (2015) Influence of depression in mild Parkinson’s disease on longitudinal motor and cognitive function. Parkinsonism Relat Disord 21(9):1056–1060. https://doi.org/10.1016/j.parkreldis.2015.06.014
Nie K, Gao Y, Mei M, Guo M, Huang Z, Wang L, Wang L (2019) The clinical characteristics and cognitive features of mild cognitive impairment in Parkinson’s disease and the analysis of relevant factors. J Clin Neurosci 63:142–148. https://doi.org/10.1016/j.jocn.2019.01.021
Papapetropoulos S, Ellul J, Argyriou AA, Chroni E, Lekka NP (2006) The effect of depression on motor function and disease severity of Parkinson’s disease. Clin Neurol Neurosurg 108(5):465–469. https://doi.org/10.1016/j.clineuro.2005.08.002
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601. https://doi.org/10.1002/mds.26424
Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C (2020) Understanding the links between cardiovascular disease and Parkinson’s disease. Mov Disord 35(1):55–74. https://doi.org/10.1002/mds.27836
Prabhakar V, Gupta D, Kanade P, Radhakrishnan M (2015) Diabetes-associated depression: the serotonergic system as a novel multifunctional target. Ind J Pharmacol 47(1):4–10. https://doi.org/10.4103/0253-7613.150305
Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Wittchen HU (2010) Frequency of dementia, depression, and other neuropsychiatric symptoms in 1449 outpatients with Parkinson’s disease. J Neurol 257(7):1073–1082. https://doi.org/10.1007/s00415-010-5465-z
Roheger M, Kalbe E, Liepelt-Scarfone I (2018) Progression of cognitive decline in Parkinson’s disease. J Parkinsons Dis 8(2):183–193. https://doi.org/10.3233/jpd-181306
Sakuta H, Suzuki K, Miyamoto T, Miyamoto M, Numao A, Fujita H, Hirata K (2017) Serum uric acid levels in Parkinson’s disease and related disorders. Brain Behav 7(1):e00598. https://doi.org/10.1002/brb3.598
Sampat R, Young S, Rosen A, Bernhard D, Millington D, Factor S, Jinnah HA (2016) Potential mechanisms for low uric acid in Parkinson disease. J Neural Transm (vienna) 123(4):365–370. https://doi.org/10.1007/s00702-015-1503-4
Santiago JA, Potashkin JA (2015) Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson’s disease patients. PLoS ONE 10(11):e0142582. https://doi.org/10.1371/journal.pone.0142582
Saredakis D, Collins-Praino LE, Gutteridge DS, Stephan BCM, Keage HAD (2019) Conversion to MCI and dementia in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 65:20–31. https://doi.org/10.1016/j.parkreldis.2019.04.020
Schlachetzki JC, Winkler J (2015) The innate immune system in Parkinson’s disease: a novel target promoting endogenous neuroregeneration. Neural Regen Res 10(5):704–706. https://doi.org/10.4103/1673-5374.156958
Schrag A, Taddei RN (2017) Depression and anxiety in Parkinson’s disease. Int Rev Neurobiol 133:623–655. https://doi.org/10.1016/bs.irn.2017.05.024
Simon DK, Tanner CM, Brundin P (2020) Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med 36(1):1–12. https://doi.org/10.1016/j.cger.2019.08.002
Soares NM, Pereira GM, Altmann V, de Almeida RMM, Rieder CRM (2019) Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson’s disease: a systematic review. J Neural Transm (vienna) 126(3):219–232. https://doi.org/10.1007/s00702-018-1947-4
Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (vienna) 124(8):901–905. https://doi.org/10.1007/s00702-017-1686-y
Vriend C, Raijmakers P, Veltman DJ, van Dijk KD, van der Werf YD, Foncke EM, van den Heuvel OA (2014) Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry 85(2):159–164. https://doi.org/10.1136/jnnp-2012-304811
Walter U, Heilmann R, Kaulitz L, Just T, Krause BJ, Benecke R, Höppner J (2015) Prediction of Parkinson’s disease subsequent to severe depression: a ten-year follow-up study. J Neural Transm (vienna) 122(6):789–797. https://doi.org/10.1007/s00702-014-1313-0
Wang S, Mao S, Xiang D, Fang C (2018) Association between depression and the subsequent risk of Parkinson’s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 86:186–192. https://doi.org/10.1016/j.pnpbp.2018.05.025
Watson GS, Leverenz JB (2010) Profile of cognitive impairment in Parkinson’s disease. Brain Pathol 20(3):640–645. https://doi.org/10.1111/j.1750-3639.2010.00373.x
Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, Jiao L (2017) Serum uric acid levels in patients with Parkinson’s disease: a meta-analysis. PLoS ONE 12(3):e0173731. https://doi.org/10.1371/journal.pone.0173731
Xiao M, Wang Q, Ren W, Zhang Z, Wu X, Wang Z, He J (2018) Impact of prediabetes on poststroke depression in Chinese patients with acute ischemic stroke. Int J Geriatr Psychiatry 33(7):956–963. https://doi.org/10.1002/gps.4878
Yang L, Chen Z, Li B, Wang M, Yu L, Wan Y, Wang X (2017) Multiple evidences for association between cognitive impairment and dysglycemia in Parkinson’s disease: implications for clinical practice. Front Aging Neurosci 9:355. https://doi.org/10.3389/fnagi.2017.00355
Yu J, Li J, Huang X (2012) The Beijing version of the montreal cognitive assessment as a brief screening tool for mild cognitive impairment: a community-based study. BMC Psychiatry 12:156. https://doi.org/10.1186/1471-244x-12-156
Zhang YX, Wang SR (2019) Large body mass index and waist circumference are associated with high blood pressure and impaired fasting glucose in young Chinese men. Blood Press Monit 24(6):289–293. https://doi.org/10.1097/MBP.0000000000000404
Zhu KD, van Hilten JJ, Marinus J (2016) Associated and predictive factors of depressive symptoms in patients with Parkinson’s disease. J Neurol 263(6):1215–1225. https://doi.org/10.1007/s00415-016-8130-3
Acknowledgements
We thank all the study participants for their cooperation.
Funding
This study was supported by National Natural Science Foundation of China (81801323), Tianjin Science and Technology Talent training Project (KJ20067).
Author information
Authors and Affiliations
Contributions
JL and SL was responsible for study concept and design, drafting of the manuscript and study supervision. CY and LN collected data and prepared the initial draft of the manuscript. YF and XZ processed the blood sample. JY, PZ, XS and YM collected and interpreted data. All authors have contributed to and have approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors state that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Yao, C., Niu, L., Fu, Y. et al. Cognition, motor symptoms, and glycolipid metabolism in Parkinson’s disease with depressive symptoms. J Neural Transm 129, 563–573 (2022). https://doi.org/10.1007/s00702-021-02437-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-021-02437-6